Loading...
COHANCE logo

Cohance Lifesciences LimitedNSEI:COHANCE Stock Report

Market Cap ₹202.9b
Share Price
₹530.30
n/a
1Y-58.2%
7D0.02%
Portfolio Value
​
View

Cohance Lifesciences Limited

NSEI:COHANCE Stock Report

Market Cap: ₹202.9b

Cohance Lifesciences (COHANCE) Stock Overview

Engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. More details

COHANCE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance1/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 45.92% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Profit margins (14.6%) are lower than last year (25.3%)


COHANCE Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

COHANCE logo
Cohance Lifesciences

COHANCE: New Facility Expansions Will Drive Future Opportunity And Margins

Key Takeaways Strategic acquisitions and entry into high-growth segments enhance revenue and margins by tapping into high-value markets like oligonucleotides and ADCs. Diversification and expansion into specialty segments with differentiated technology and M&A bolster competitive advantage and drive predictable, accelerated growth. Strategic acquisition reliance and volatile demand may strain cash flow, impacting financial stability, margins, and long-term earnings if expected synergies aren't realized.
View narrative
₹801.11
FV
33.8% undervalued intrinsic discount
56.39%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
View Stock Community

Cohance Lifesciences Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cohance Lifesciences
Historical stock prices
Current Share Price₹530.30
52 Week High₹1,328.00
52 Week Low₹521.30
Beta0.52
1 Month Change-13.84%
3 Month Change-46.47%
1 Year Change-58.20%
3 Year Change11.55%
5 Year Change29.31%
Change since IPO214.67%

Recent News & Updates

Cohance Lifesciences' (NSE:COHANCE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 20
Cohance Lifesciences' (NSE:COHANCE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

What Does The Future Hold For Cohance Lifesciences Limited (NSE:COHANCE)? These Analysts Have Been Cutting Their Estimates

Nov 14
What Does The Future Hold For Cohance Lifesciences Limited (NSE:COHANCE)? These Analysts Have Been Cutting Their Estimates

Recent updates

Cohance Lifesciences' (NSE:COHANCE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Nov 20
Cohance Lifesciences' (NSE:COHANCE) Sluggish Earnings Might Be Just The Beginning Of Its Problems

What Does The Future Hold For Cohance Lifesciences Limited (NSE:COHANCE)? These Analysts Have Been Cutting Their Estimates

Nov 14
What Does The Future Hold For Cohance Lifesciences Limited (NSE:COHANCE)? These Analysts Have Been Cutting Their Estimates

Market Participants Recognise Cohance Lifesciences Limited's (NSE:COHANCE) Revenues

Oct 28
Market Participants Recognise Cohance Lifesciences Limited's (NSE:COHANCE) Revenues
User avatar

Converting Increased RFPs Into Contracts Will Strengthen Future Prospects

Strategic acquisitions and diversification into niche markets enhance Suven's revenue potential and improve margins through high-value offerings.

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Dec 15
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Aug 03
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

May 12
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Mar 26
Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected

Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

Mar 07
Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching

These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Nov 30
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely

Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Sep 03
Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?

Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Aug 04
Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly

Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

Jun 11
Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report

With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Apr 13
With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting

Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Mar 08
Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?

Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Feb 08
Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?

Shareholder Returns

COHANCEIN PharmaceuticalsIN Market
7D0.02%-0.4%-0.3%
1Y-58.2%-2.2%-2.3%

Return vs Industry: COHANCE underperformed the Indian Pharmaceuticals industry which returned -2.2% over the past year.

Return vs Market: COHANCE underperformed the Indian Market which returned -2.3% over the past year.

Price Volatility

Is COHANCE's price volatile compared to industry and market?
COHANCE volatility
COHANCE Average Weekly Movement4.8%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement5.2%
10% most volatile stocks in IN Market8.6%
10% least volatile stocks in IN Market3.1%

Stable Share Price: COHANCE has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: COHANCE's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19891,212Yann D'Hervewww.cohance.com

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies.

Cohance Lifesciences Limited Fundamentals Summary

How do Cohance Lifesciences's earnings and revenue compare to its market cap?
COHANCE fundamental statistics
Market cap₹202.88b
Earnings (TTM)₹1.77b
Revenue (TTM)₹12.11b
114.6x
P/E Ratio
16.8x
P/S Ratio

Is COHANCE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
COHANCE income statement (TTM)
Revenue₹12.11b
Cost of Revenue₹3.37b
Gross Profit₹8.73b
Other Expenses₹6.96b
Earnings₹1.77b

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)4.63
Gross Margin72.13%
Net Profit Margin14.62%
Debt/Equity Ratio5.6%

How did COHANCE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/15 20:15
End of Day Share Price 2025/12/15 00:00
Earnings2025/09/30
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cohance Lifesciences Limited is covered by 12 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harith AhamedAvendus Spark
Vijayaraghavan SwaminathanAvendus Spark
Rohit BhatBatlivala & Karani Securities India Pvt. Ltd.